Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-03-22
2011-03-22
Kemmerer, Elizabeth C. (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007920, C435S007930, C530S387100, C530S387900, C530S388100, C530S387300, C530S389100
Reexamination Certificate
active
07910321
ABSTRACT:
The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.
REFERENCES:
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5310662 (1994-05-01), Evans et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5359039 (1994-10-01), Smith et al.
patent: 5395760 (1995-03-01), Smith et al.
patent: 5447851 (1995-09-01), Buetler et al.
patent: 5464938 (1995-11-01), Smith et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 6303336 (2001-10-01), Spear et al.
patent: 7427492 (2008-09-01), Ni et al.
patent: 7429646 (2008-09-01), Ni et al.
patent: 7446169 (2008-11-01), Ni et al.
patent: 2009/0092608 (2009-04-01), Ni et al.
patent: 2009/0131319 (2009-05-01), Ni et al.
patent: 2045869 (1991-12-01), None
patent: 0393438 (1990-10-01), None
patent: 0555880 (1993-08-01), None
patent: 0585939 (1994-03-01), None
patent: 0 822 984 (1998-02-01), None
patent: WO-91/02078 (1991-02-01), None
patent: WO-91/09045 (1991-06-01), None
patent: WO-93/20219 (1993-10-01), None
patent: WO-94/09137 (1994-04-01), None
patent: WO-94/13808 (1994-06-01), None
patent: WO-96/34095 (1996-10-01), None
patent: WO-97/04658 (1997-02-01), None
patent: WO-97/06251 (1997-02-01), None
patent: WO-98/18824 (1998-05-01), None
patent: WO-98/25967 (1998-06-01), None
patent: WO-98/51346 (1998-11-01), None
US 5,843,791, 12/1998, Hauptmann et al. (withdrawn)
Zhang (2004, Curr. Opin. Struct. Biol. 14:154-160).
Matsubara, et al., “cDNA analysis in the human genome project,” Gene, 135(2):265-274 (Dec. 15, 1993).
Matsubara, et al., “Identification of new genes by systematic analysis of cDNAs and database construction,” Current Opinion in Biotechnology, 4(6):672-677 (Dec. 1, 1993).
Okubo, et al., “Large scale cDNA sequencing for analysis of quantitative and qualitative aspects of gene expression,” Nature Genetics, 2(3):173-179 (Nov. 1, 1992).
Weinstock, et al., “cDNA sequencing: a means of understanding cellular physiology,” Current Opinion in Biotechnology, 5(6):599-603 (Jan. 1, 1994).
Adams, et al., “Complementary DNA sequencing: expressed sequence tags and human genome project,”Science, 252:1651-1656 (1991).
Adams, et al., “Sequence identification of 2,375 human brain genes,”Nature, 355:632-634 (1992).
Aggarwal, et al., “Tumor necrosis factors: developments during the last decade,”Eur. Cytokine Netw., 7(2):93-124 (May 1996).
Altschul, et al., “Basic local alignment search tool,”J. Mol. Biol., 215:403-410 (1990).
Armitage, R.J., “Tumor necrosis factor receptor superfamily members and their ligands,”Curr. Opin. Immunol., 6:407-413 (Jun. 1994).
Ashkenazi, et al., “Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin,”Proc. Natl. Acad. Sci. USA, 88:10535-10539 (1991).
Baens, et al., “Construction and evaluation of a hncDNA library of human 12p transcribed sequences derived from a somatic cell hybrid,”Genomics, 16:214-218 (1993).
Baker, et al., “Chromosomal location of the human tumor necrosis factor receptor genes,”Cytogenet. Cell Genet., 57:117-118 (1991).
Banchereau, et al., “Long-term human B cell lines dependent on interleukin-4 and antibody to CD40,”Science, 251:70-72 (1991).
Banner, et al., “Crystal structure of the solluble human 55 kd receptor-human TNFβ complex: implications for TNF receptor activation,”Cell, 73:431-445 (1993).
Baum, et al., “Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34,”EMBO J., 13(17):3992-4001 (Sep. 1994).
Benjamin, et al., “A plasticity window for blood vessel remodeling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF,”Development, 125(9):1591-1598 (May 1998).
Birkeland, et al., “Gene structure and chromosomal localization of the mouse homologue of rat OX40 protein,”Eur. J. Immunol., 25:926-930 (Apr. 1995).
Bork, P., “Powers and pitfalls in sequence analysis: the 70% hurdle,”Genome Res., 10(4):398-400 (Apr. 2000).
Bork, P.,Trends Genet., 12:425-427 (1998).
Brenner, S.E., “Errors in genome annotation,”Trends Genet., 15(4):132-133 (Apr. 1999).
Camerini, et al., “The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family,”J. Immunol., 147(9):3165-3169 (1991).
Chang, et al., “Identification of a new member of the steroid receptor superfamily by cloning and sequence analysis,”Biochem. Biophys. Res. Comm., 155(2):971-977 (Sep. 15, 1988).
Chinnaiyan, et al., “Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95,”Science, 274:990-992 (1996).
Doerks, et al., “Protein annotation: detective work for function prediction,”Trends Genet., 14(6):248-250 (Jun. 1998).
Dürkop, et al., “Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's Disease,”Cell, 68:421-427 (1992).
Engelmann, et al., “Two tumor necrosis factor-binding proteins purified from human urine,”J. Biol. Chem., 265(3):1531-1536 (1990).
Feinstein, et al., “The death domain: a module shared by proteins with diverse cellular functions,”TIBS, 20:342-344 (Sep. 1995).
Førre, et al., “New treatment possibilities in rheumatoid arthritis,”Scan. J. Rheumatol., 29:73-84 (2000).
Gillette-Ferguson, et al., “A specific intercellular pathway of apoptotic cell death is defective in the mature peripheral T cells of autoimmuneIprandgldmice,”Eur. J. Immunol., 24:1181-1185 (May 1994).
Goodwin, et al., “Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor,”Eur. J. Immunol., 23:2631-2641 (1993).
Gruss, et al., “Pleiotropic Effects of the CD30 Ligand on CD30-Expressing Cells and Lymphoma Cell Lines,”Blood, 83:2045-2056 (Apr. 1994).
Himmler, et al., “Molecular Cloning and Expression of Human and Rat Tumor Necrosis Factor Receptor Chain (p60) and Its Soluble Derivative, Tumor Necrosis Factor-Binding Protein,”DNA and Cell Biol., 9:705-715 (1990).
Hohmann, et al., “Two Different Cell Types Have Different Major Receptors for Human Tumor Necrosis Factor (TNFα),”J. Biol. Chem., 264:14927-14934 (1989).
Howard, et al., “Vaccinia Virus Homologues of the Shope Fibroma Virus Inverted Terminal Repeat Proteins and a Discontinuous ORF Related to the Tumor Necrosis Factor Receptor Family,”Virol., 180:633-647 (1991).
Hsu, et al., “Differential Expression and Ligand Binding Properties of Tumor Necrosis Factor Receptor Chimeric Mutants,”J. Biol. Chem., 268:16430-16436 (1993).
Hu, et al., “Cowpox Virus Contains Two Copies of an Early Gene Encoding a Soluble Secreted Form of the Type II TNF Receptor,”Virol., 204:343-356 (Oct. 1994).
Inui, et al., “Identification of the intracytoplasmic region essential for signal transduction through a B cell activation molecule, CD40,”Eur. J. Immunol., 20:1747-1753 (1990).
Itoh, et al., “The Polypeptide Encoded by the cDNA for Human
Gentz Reiner L.
Hurle Mark
Lyn Sally Doreen P.
Ni Jian
Rosen Craig A.
Human Genome Sciences Inc.
Kemmerer Elizabeth C.
SmithKline Beecham Corporation
LandOfFree
Methods of determining the level of human tumor necrosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of determining the level of human tumor necrosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of determining the level of human tumor necrosis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2717384